DelveInsight’s, “Diabetic Retinopathy Pipeline Insight 2024” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Diabetic Retinopathy pipeline landscape. It covers the Diabetic Retinopathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Retinopathy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Diabetic Retinopathy Pipeline Report
- DelveInsight’s Diabetic Retinopathy pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Diabetic Retinopathy treatment.
- The leading companies working in the Diabetic Retinopathy Market include Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others.
- Promising Diabetic Retinopathy Pipeline Therapies in the various stages of development include Runcaciguat (BAY1101042), OTT166, COLIRIOBCN070660, Brimonidine, and others.
- March 2024:- Digital Diagnostics Inc.- Diabetes affects 30.3 million people or 9.3% of the population of the United States. Results of a study by the Eye Diseases Prevalence Research Group reveal that 40% of diabetes patients have some degree of diabetic retinopathy (DR) and that as many as 8% have severe, vision-threatening forms of DR.
Request a sample and discover the recent advances in Diabetic Retinopathy Treatment Drugs @ Diabetic Retinopathy Pipeline Report
In the Diabetic Retinopathy pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic Retinopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Diabetic Retinopathy Overview
Diabetic retinopathy (DR) is a major complication of diabetes mellitus (DM), which remains a leading cause of visual loss in working-age populations. The retina contains photoreceptor cells that function in the process of visual transduction, i.e., transforming light signals to nerve impulses eventually transmitted from the optic nerve to the brain forming an image.
Find out more about Diabetic Retinopathy Therapeutics Assessment @ Diabetic Retinopathy Preclinical and Discovery Stage Products
Diabetic Retinopathy Emerging Drugs Profile
- KSI-301: Kodiak Sciences
- Brolucizumab: Novartis
- RGX 314: Regenxbio Inc.
- OTT-166: OcuTerra Therapeutics
- OTX-TKI: Ocular Therapeutix
Diabetic Retinopathy Pipeline Therapeutics Assessment
There are approx. 50+ key companies which are developing the Diabetic Retinopathy therapies. The Diabetic Retinopathy companies which have their Diabetic Retinopathy drug candidates in the most advanced stage, i.e. phase III include, Kodiak Sciences.
DelveInsight’s Diabetic Retinopathy pipeline report covers around 55+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Diabetic Retinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Diabetic Retinopathy Pipeline Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Learn more about the emerging Diabetic Retinopathy Pipeline Therapies @ Diabetic Retinopathy Clinical Trials Assessment
Scope of the Diabetic Retinopathy Pipeline Report
- Coverage- Global
- Diabetic Retinopathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Diabetic Retinopathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Diabetic Retinopathy Companies- Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others.
- Diabetic Retinopathy Pipeline Therapies- Runcaciguat (BAY1101042), OTT166, COLIRIOBCN070660, Brimonidine, and others.
Dive deep into rich insights for new drugs for Diabetic Retinopathy Treatment, Visit @ Diabetic Retinopathy Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Diabetic Retinopathy: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Diabetic Retinopathy– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- KSI-301: Kodiak Sciences
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- RGX 314: Regenxbio Inc
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- OTX-TKI: Ocular Therapeutix
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Diabetic Retinopathy Key Companies
- Diabetic Retinopathy Key Products
- Diabetic Retinopathy- Unmet Needs
- Diabetic Retinopathy- Market Drivers and Barriers
- Diabetic Retinopathy- Future Perspectives and Conclusion
- Diabetic Retinopathy Analyst Views
- Diabetic Retinopathy Key Companies
- Appendix
For further information on the Diabetic Retinopathy Pipeline therapeutics, reach out to Diabetic Retinopathy Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/